Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9. (Q54262056)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/26126970

Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/26126970

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Jame Abraham

1

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/26126970

André Robidoux

2

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/26126970

Antoinette R Tan

3

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/26126970

Steven Limentani

4

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/26126970

Keren Sturtz

5

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/26126970

Ibrahim Shalaby

6

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/26126970

Hope Alcorn

7

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/26126970

Marc E Buyse

8

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/26126970

Norman Wolmark

9

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/26126970

Samuel A Jacobs

10

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/26126970

language of work or name

0 references

publication date

1 July 2015

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/26126970

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/26126970

152

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/26126970

2

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/26126970

399-405

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/26126970

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3466-4

21 January 2018

Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3466-4

21 January 2018

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3466-4

21 January 2018

Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3466-4

21 January 2018

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3466-4

21 January 2018

A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3466-4

21 January 2018

Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3466-4

21 January 2018

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3466-4

21 January 2018

Primary systemic therapy of breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3466-4

21 January 2018

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3466-4

21 January 2018

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3466-4

21 January 2018

Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3466-4

21 January 2018

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3466-4

21 January 2018

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3466-4

21 January 2018

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3466-4

21 January 2018

A three-outcome design for phase II clinical trials.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3466-4

21 January 2018

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3466-4

21 January 2018

First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3466-4

21 January 2018

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3466-4

21 January 2018

Identifiers

10.1007/S10549-015-3466-4

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/26126970

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/26126970

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54262056&oldid=2212402863"